Lung

Lung

We’re here for you. Call us at 844-346-7222 or

Clinical Trials for Lung Cancer Treatments

Every year, there are more than 200,000 new cases of lung cancer in the U.S. The good news is that over the past decade, lung cancer death rates have been dropping thanks to improvements in treatments made possible by clinical trials. At Regional Cancer Care Associates, we conduct more than 300 advanced clinical trials. To see if a lung cancer clinical trial is right for you, contact RCCA at 201-669-4706.

Defining Clinical Trial

Clinical trials are research studies that test the safety and effectiveness of new medical approaches to prevent, detect, diagnose and cure certain diseases. When it comes to lung cancer, these studies provide data that help give medical professionals insight into new drugs, treatment techniques and devices and their ability to treat cancer patients.

Before being offered as a clinical trial, the therapies must undergo a lengthy research process in a laboratory. When they finally become available to the medical community, these treatments will be meticulously designed. Prior to giving consent for a clinical trial, patients will receive in-depth information about the various aspects of the treatment, including all possible risks and benefits.

The Clinical Trial Advantage

Lung cancer treatments are constantly being developed, but before they can be approved, they must be tested for human use. As a participant in a clinical trial, you’ll receive access to innovative treatments that have yet to hit the market. Besides presenting you with cutting-edge medical therapies, clinical trials give you the chance to make a difference in the future of lung cancer care.

Clinical trials are also considered an affordable option for lung cancer patients. In fact, all cost of care is covered by the sponsoring company. At RCCA specifically, we always put the safety and wellbeing of our clinical trial participants first – an institutional review board and scientific experts will closely monitor trial protocols to ensure strict regulations are enforced throughout the process.

Lung Cancer Clinical Trials at RCCA

Want more information about enrolling in a lung cancer clinical trial? Make an appointment at your nearest RCCA location to speak with a cancer care specialist about your clinical trial eligibility.

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

5 Clinical Trials
Lung II Accepting Patients
nct/study# NCT04623775 / CA224-104

A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with Stage IV or Recurrent NSCLC

Learn More
Lung III Accepting Patients
nct/study# NCT03906071 / 516-005

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Learn More
Lung N/A Accepting Patients
nct/study# NCT04894591 / JZP712-402 EMERGE

Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca (EMERGE 402)

Learn More
Lung II Accepting Patients
nct/study# NCT04863248 / G1T28-210

A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)

Learn More
Lung II Active
nct/study# NCT04919811 / AB-106-G208

Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.